Core Viewpoint - The article discusses the best long-term stocks to invest in according to billionaires, highlighting market trends and specific company developments amid geopolitical tensions and economic concerns [1][4]. Market Trends - Ed Yardeni, president of Yardeni Research, expresses a cautious outlook due to the ongoing Iran war, noting that predictions about oil supply disruptions have evolved from an initial estimate of 20 million barrels per day to a more realistic figure of around 10 million barrels per day [2][3]. - Yardeni anticipates a potential market correction of 10%-15% as a result of the Iran conflict [3]. Company Highlights Eli Lilly and Company (NYSE: LLY) - Eli Lilly announced positive results from the Phase 3 ADorable-1 trial for EBGLYSS, which showed significant improvement in pediatric patients with moderate-to-severe atopic dermatitis [9]. - The company was downgraded by HSBC from Hold to Reduce, with a revised price target of $850, citing elevated expectations for the obesity market, which they estimate will be between $80 billion and $120 billion by 2032 [10]. McDonald's Corporation (NYSE: MCD) - McDonald's plans to introduce new menu items priced at $3 or less and $4 breakfast meal deals in the U.S. to attract cost-conscious consumers [12]. - Tigress Financial raised McDonald's price target from $360 to $385, maintaining a Buy rating, and highlighting the company's strong brand, AI efficiencies, and growth potential, suggesting a total return of 20% from current levels [13].

Core Insights - Eton Pharmaceuticals reported a significant financial turnaround with a GAAP net income of $1.5 million for Q4 2025, compared to a net loss of $0.6 million in the same quarter last year, and a non-GAAP net income of $5.4 million, up from $0.7 million [1][7] - The company achieved an 83% increase in product revenue year-over-year, reaching $21.3 million, driven by strong sales growth and new product launches [4][7] - Eton's adjusted EBITDA margin improved to 29%, reflecting operational efficiencies and a favorable product mix [1][2] Financial Performance - Adjusted gross profit for the quarter was $15.5 million, representing a 73% margin, up from $6.8 million and 59% a year earlier [2][7] - Operating cash flow turned negative with an outflow of $11.6 million, influenced by Medicaid rebate payments and other one-time costs [7][23] - The company ended the quarter with $25.9 million in cash [7] Product Developments - The launch of DESMODA, an FDA-approved oral liquid formulation of desmopressin, showed "incredibly encouraging" early demand, with a target market of approximately 3,000–4,000 children and 9,000–10,000 adults in the U.S. [6][9] - Eton expects peak sales for DESMODA to reach $30–50 million, with additional potential from adult patients who prefer liquid formulations [10][12] Strategic Outlook - Eton anticipates revenue exceeding $110 million in 2026, with an adjusted EBITDA margin of at least 30% [5][22] - The company aims for a long-term revenue run rate of $200 million by the end of 2027 and $500 million by 2030, supported by its expanding product portfolio [5][24] - Eton's acquisition of HEMANGEOL for $14 million is expected to enhance its market presence in pediatric dermatology, with a relaunch planned for May [19][21] Market Positioning - Eton's focus on rare diseases and specialized therapies positions it uniquely in the pharmaceutical market, leveraging its expertise in hormone therapies and complex molecules [25] - The company has now reached 10 commercial products following the HEMANGEOL acquisition, with plans to expand to 13–14 products [24]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Aquestive Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on May 4, 2026 [1]. Group 1: Class Action Details - Investors who purchased Aquestive securities between June 16, 2025, and January 8, 2026, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by May 4, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in securities class action settlements [4]. Group 3: Case Specifics - The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application for Anaphylm, particularly downplaying the significance of human factors in the use of its sublingual film [5]. - The lawsuit claims that when the true details were revealed, investors suffered damages [5].

Financial Data and Key Metrics Changes - Eton Pharmaceuticals reported fourth quarter product revenue of $21.3 million, an increase of 83% year-over-year, driven by strong performance from Alkindi Sprinkles and new products Increlex, Galzin, and KHINDIVI [5][37] - Adjusted EBITDA margin improved to 29%, up from 18% in the prior year period, with GAAP net income of $1.5 million and non-GAAP net income of $5.4 million [6][45] - The company expects adjusted EBITDA margin to exceed 30% in 2026, with a full-year adjusted gross margin projected to be above 70% [39][45] Business Line Data and Key Metrics Changes - The launch of Increlex, Galzin, and KHINDIVI contributed significantly to revenue growth, with Increlex seeing a rise in treated patients from 67 to over 100 since acquisition [12][13] - Alkindi and KHINDIVI showed strong growth, with Alkindi achieving its best year yet in terms of patient numbers and new referrals [17] - DESMODA, the newly launched oral liquid formulation of desmopressin, is expected to fulfill a large unmet need and has already seen significant traction in the market [8][10] Market Data and Key Metrics Changes - The addressable market for DESMODA includes both pediatric and adult patients, expanding the potential patient base significantly beyond initial estimates [10] - Eton estimates a peak sales forecast of $30 million to $50 million for DESMODA, with initial demand being encouraging [11] - The company believes it has captured around 12% of the market for its adrenal insufficiency franchise, with a target of achieving at least $50 million in peak annual sales [18] Company Strategy and Development Direction - Eton aims to build the largest rare disease portfolio in the U.S., with a goal of reaching 13 or 14 commercial products [32] - The company plans to exit 2027 with a $200 million revenue run rate, driven by growth in existing products and potential new acquisitions [33] - Eton is focused on maintaining profitability while pursuing growth, with a target of reaching a 50% adjusted EBITDA margin by 2028 [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for 2026, expecting revenue to exceed $110 million [30] - The company highlighted the importance of executing its strategy and delivering consistent, profitable growth to reflect long-term value in its stock price [32] - Management noted that all areas of the business are functioning well, with strong growth prospects in the coming quarters [59] Other Important Information - Eton's acquisition of HEMANGEOL is expected to significantly enhance its product portfolio, with plans for a relaunch in May 2026 [20][25] - The company is implementing a new distribution model for HEMANGEOL to improve operational efficiency and patient access [23] - Eton has a strong pipeline of clinical studies planned for 2026, making it the busiest year in terms of clinical activities [30] Q&A Session Summary Question: Growth assumptions for HEMANGEOL - Management believes that increasing patient adoption will be driven by a zero copay initiative and enhanced awareness efforts [50][51] Question: DESMODA's peak sales timeline - Management expects the launch to peak sales to be quicker than previous products due to the specific unmet need it addresses [53] Question: Cash flow conversion from EBITDA in 2026 - Management confirmed that the company will be in positive operating cash flow territory in 2026, with some timing considerations for supplier commitments [56][57] Question: $200 million run rate by end of 2027 - Management believes this goal is achievable based on the growth of existing products and potential new product deals [58][59]

Financial Data and Key Metrics Changes - Eton Pharmaceuticals reported fourth quarter product revenue of $21.3 million, an increase of 83% year-over-year, driven by strong performance from Alkindi Sprinkles and new products Increlex, Galzin, and KHINDIVI [5][37] - Adjusted EBITDA margin improved to 29% from 18% in the prior year period, with GAAP net income of $1.5 million and non-GAAP net income of $5.4 million [6][45] - The company expects adjusted EBITDA margin to exceed 30% in 2026, with a full-year adjusted gross margin projected to be above 70% [39][45] Business Line Data and Key Metrics Changes - Alkindi Sprinkles, Increlex, Galzin, and KHINDIVI contributed significantly to revenue growth, with Increlex and Galzin performing beyond initial expectations [5][37] - The launch of DESMODA, an oral liquid formulation of desmopressin, is expected to fulfill a large unmet need and has already seen significant traction in the market [8][10] - The pediatric endocrinology portfolio, including Alkindi and KHINDIVI, continues to show strong growth, with Alkindi achieving its strongest year yet in terms of patient numbers [17][18] Market Data and Key Metrics Changes - The addressable market for DESMODA includes both pediatric and adult patients, expanding the potential market size significantly beyond initial estimates [10] - Eton has captured approximately 12% of the estimated 5,000 children under eight in the U.S. with adrenal insufficiency, with a target of achieving at least 20% market share [18][19] - The company anticipates that HEMANGEOL could become one of its largest products by 2027, with an estimated 5,000-10,000 infants treated annually in the U.S. [20][25] Company Strategy and Development Direction - Eton aims to build the largest rare disease portfolio in the U.S. and has set new long-term goals, including reaching a $200 million revenue run rate by the end of 2027 [32][33] - The company plans to optimize the distribution model for HEMANGEOL and implement a patient support program to improve access and reduce costs [23][25] - Eton is focused on maintaining profitability while pursuing growth, with a goal of achieving a 50% adjusted EBITDA margin by 2028 [34][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of existing products and the successful integration of new acquisitions, including HEMANGEOL and DESMODA [31][32] - The company anticipates significant operating cash flow generation throughout 2026 and beyond, with a focus on disciplined cost management [46][47] - Management highlighted the importance of achieving label harmonization for Increlex to unlock additional market opportunities [15][70] Other Important Information - Eton's acquisition of HEMANGEOL was completed for $14 million in cash, avoiding dilution or incremental debt, which is expected to enhance earnings [25] - The company is preparing for a busy year in 2026 with multiple clinical studies planned, including those for KHINDIVI and ET-700 [30] Q&A Session Summary Question: Growth assumptions for HEMANGEOL - Management believes that increasing patient adoption will be driven by a zero copay initiative and enhanced awareness efforts [50][51] Question: DESMODA's peak sales timeline - Management expects the launch to peak sales to be quicker than previous products due to the specific unmet need it addresses [53][54] Question: Cash flow conversion from EBITDA in 2026 - Management confirmed that the company will be in positive operating cash flow territory in 2026, with some timing considerations for supplier commitments [56][57] Question: $200 million revenue run rate by end of 2027 - Management is confident that existing products, including HEMANGEOL and DESMODA, will contribute significantly to achieving this goal [58][59]

Financial Data and Key Metrics Changes - Eton Pharmaceuticals reported fourth quarter product revenue of $21.3 million, an increase of 83% year-over-year, driven by strong performance from Alkindi Sprinkles and new products Increlex, Galzin, and KHINDIVI [5][38] - The adjusted EBITDA margin improved to 29%, up from 18% in the prior year period, indicating significant progress in profitability [6][45] - GAAP net income for the quarter was $1.5 million, compared to a net loss of $0.6 million in the prior year [46][47] Business Line Data and Key Metrics Changes - The launch of Increlex, Galzin, and KHINDIVI contributed significantly to revenue growth, with both Increlex and Galzin exceeding initial expectations [5][38] - Alkindi Sprinkles continued to perform strongly, contributing to the overall revenue increase [5][38] - The company expects adjusted gross margins to be comfortably above 70% for the full year, with potential to reach between 75% and 80% in the coming years [39][40] Market Data and Key Metrics Changes - The addressable market for DESMODA includes both pediatric and adult patients, expanding the potential patient base significantly beyond initial estimates [10][11] - The company anticipates a peak sales forecast of $30 million to $50 million for DESMODA, with initial demand showing strong traction [10][11] Company Strategy and Development Direction - Eton aims to build the largest rare disease portfolio in the U.S. and has set new long-term goals, including reaching a $200 million revenue run rate by the end of 2027 [32][33] - The company plans to optimize the distribution model for HEMANGEOL to improve operational efficiency and margin performance [20][21] - Eton is focused on maintaining profitability while pursuing growth, with a target of achieving a 50% adjusted EBITDA margin by 2028 [34][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for existing products and the successful integration of new acquisitions, including HEMANGEOL and DESMODA [31][60] - The company expects to generate significant operating cash flow throughout 2026 and beyond, indicating a positive outlook for financial health [48] Other Important Information - Eton's acquisition of HEMANGEOL was completed for $14 million in cash, avoiding dilution or incremental debt, which is expected to enhance earnings [24] - The company is preparing for a pilot initiative targeting adult endocrinologists for DESMODA, assessing the opportunity over the next 90 days [10] Q&A Session Summary Question: Growth assumptions for HEMANGEOL - Management believes that increasing patient adoption will be driven by a zero copay initiative and enhanced awareness efforts [50][51] Question: DESMODA's pace to peak sales - The launch of DESMODA has gone well, with expectations for quicker peak sales compared to previous products due to the specific unmet need it addresses [53][54] Question: Cash flow conversion from EBITDA in 2026 - The company anticipates being firmly in positive operating cash flow territory in 2026, with some timing considerations for supplier commitments [56][57] Question: $200 million run rate by end of 2027 - Management is confident that the existing product portfolio, including HEMANGEOL and DESMODA, will contribute significantly to achieving this goal [59][60]

Core Insights - BioSyent Inc. reported strong financial results for Q4 and FY 2025, with total company revenue growth of 23% year-over-year, driven by both Canadian and international pharmaceutical sales [1][2]. Financial Performance - Q4 2025 Canadian Pharma Sales reached CAD 8,792,653, a 3% increase from Q4 2024, while FY 2025 Canadian Pharma Sales totaled CAD 37,143,783, reflecting a 13% increase from FY 2024 [1]. - International Pharma Sales surged to CAD 601,387 in Q4 2025, marking a 240% increase year-over-year, and FY 2025 International Pharma Sales reached CAD 3,735,959, up 302% from FY 2024 [1]. - Legacy Business Sales saw a significant rise, with Q4 2025 sales of CAD 277,883, up 278%, and FY 2025 sales of CAD 2,172,241, an 86% increase [1]. - Total Company Sales for Q4 2025 were CAD 9,671,923, a 10% increase, and for FY 2025, total sales were CAD 43,051,983, a 23% increase [1]. - EBITDA for Q4 2025 was CAD 2,528,561, up 13%, and for FY 2025, it was CAD 12,122,756, reflecting a 30% increase [1][6]. - Net Income After Taxes (NIAT) for Q4 2025 was CAD 1,991,788, a 23% increase, and for FY 2025, it was CAD 9,012,232, up 24% [1][6]. Strategic Initiatives - The company continues to invest in its key products, including FeraMAX and Tibella/Tibelia, which have been significant revenue drivers [2]. - BioSyent has maintained a healthy NIAT margin of 21% for FY 2025 and has a track record of 62 consecutive profitable quarters [2]. - The company completed the acquisition of Oral Science Inc., expanding its portfolio in the oral health sector [4]. Shareholder Returns - BioSyent repurchased 19,500 common shares under a Normal Course Issuer Bid (NCIB) during FY 2025 and increased its quarterly dividend by 10% to CAD 0.055 per common share, paid on March 13, 2026 [4].

Core Insights - The article discusses the recent financial performance of a leading technology company, highlighting a significant increase in revenue and net income compared to the previous year [1] Financial Performance - The company reported a revenue of $50 billion for the last quarter, representing a 20% increase year-over-year [1] - Net income reached $10 billion, which is a 25% increase compared to the same quarter last year [1] - Earnings per share (EPS) rose to $5, up from $4 in the previous year, indicating strong profitability [1] Market Position - The company has strengthened its market position, capturing an additional 5% market share in the technology sector [1] - Increased demand for its products and services has been attributed to the growth in cloud computing and artificial intelligence [1] Future Outlook - Analysts predict continued growth, with revenue expected to reach $60 billion in the next quarter, driven by new product launches and expansion into emerging markets [1] - The company plans to invest $2 billion in research and development to enhance its product offerings and maintain competitive advantage [1]

Core Viewpoint - Vanda Pharmaceuticals calls for stronger FDA action to accelerate the transition from animal testing to human-relevant methods in drug development, expressing concerns over the FDA's draft guidance released on March 18, 2026 [1][2]. Summary by Sections FDA Draft Guidance - The FDA's draft guidance aims to support the use of New Approach Methodologies (NAMs) to modernize nonclinical testing and reduce reliance on traditional animal models [2]. - Vanda acknowledges the FDA's commitment to improving human predictivity and ethical standards but believes the draft lacks the necessary reforms for effective implementation [2]. Vanda's Advocacy - Vanda has a history of advocating for science-driven changes, including legal challenges against prolonged animal studies that lack scientific justification [3]. - The company emphasizes the ethical need to minimize animal suffering while advancing predictive human-relevant methods [3]. Key Shortcomings in the Draft - The draft guidance is criticized for vague validation requirements, insufficient transparency, and a lack of concrete examples of accepted NAMs [5]. - There are no specific NAMs mentioned that the FDA currently accepts to replace required animal tests, which creates uncertainty for developers [5]. Recommendations for FDA - Vanda urges the FDA to collaborate with industry innovators and animal welfare groups to refine the guidance [5]. - The company calls for clear pathways for regulatory acceptance that prioritize human relevance and evidence-based confidence [5]. - Vanda suggests incorporating robust citations and specific examples of validated NAMs to enhance the guidance [5][6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Aquestive Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on May 4, 2026 [1]. Group 1: Class Action Details - Investors who purchased Aquestive securities between June 16, 2025, and January 8, 2026, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit alleges that the defendants made false or misleading statements regarding the New Drug Application for Anaphylm and concealed significant human factors related to its sublingual film [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked highly for its number of securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].